Vimarsana
Biggest News Aggregation in the World

Current Study Design News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Current Study Design. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Current Study Design Today - Breaking & Trending Today

Investegate |Syncona Limited Announcements | Syncona Limited: Achilles data and safety committee review - Vimarsana News

Investegate |Syncona Limited Announcements | Syncona Limited: Achilles data and safety committee review

05 February 2020 Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes the announcement that its portfolio company, Achilles Therapeutics, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/II CHIRON and THETIS trials and has recommended that both clinical trials continue as planned.  The fu...

Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials - Vimarsana News

Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials

Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials Phase I/IIa CHIRON and THETIS Trials London, UK 5 February 2021 - Achilles Therapeutics ("Achilles" or the "Company"), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/IIa CHIRON and THETIS tr...